ATRA
BEARISH
$5.22
Live
Atara Biotherapeutics, Inc. · NASDAQ
Target $8.67
(+66.0%)
$4.2
52W Range
$19.14
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$37.64M
P/E
1.83
ROE
N/A
Profit margin
15.4%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and financial distress. Despite a current price of $5.22 appearing low relative to an intrinsic value estimate of $20.02, the company exhibits alarming fundamentals including negative operating margin (-102.72%), collapsing revenue (YoY growth: -91.40%), and a bearish insider selling trend. While recent earnings surprises have been positive, the long-term financial instability, lack of reliable Altman Z-Score, and deteriorating cash position overshadow any valuation appeal. The stock's technical trend is deeply bearish, and analyst consensus is only a 'hold' with limited coverage, further undermining confidence.
Key Strengths
Recent quarterly earnings have consistently beaten estimates, with an average surprise of +242% over the last four quarters
Gross margin remains relatively strong at 46.76%, suggesting some pricing power or cost control in core operations
Current price of $5.22 is significantly below the growth-based intrinsic value estimate of $20.02, implying potential upside if fundamentals stabilize
ROA of 30.86% is positive and unusually high for a biotech firm, though likely distorted by asset write-downs or accounting adjustments
Low Price/Sales ratio of 0.25 suggests the market is pricing in extreme pessimism, potentially creating contrarian opportunity
Key Risks
Piotroski F-Score of 2/9 indicates very weak financial health, with red flags across profitability, leverage, and operating efficiency
Operating margin of -102.72% reflects unsustainable cost structure and lack of path to profitability
Revenue has collapsed by 91.4% year-over-year, signaling severe commercial or operational challenges
Insiders have sold $0.61M in shares over the past 6 months with zero buys, indicating strong lack of confidence from management
Technical trend score of 0/100 and 1-year price decline of 24.7% (with 5-year loss of 98.9%) reflect deep market skepticism and momentum breakdown
AI Fair Value Estimate
Based on comprehensive analysis
$12.5
+139.5% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
55
20
30
15
0
AI Verdict
High-risk speculative position with severe financial instability outweighing any valuation discount.
Key drivers: Piotroski F-Score of 2, Revenue collapse of -91.4%, Insider selling, Negative operating margin, Lack of Altman Z-Score
Confidence
90%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- Intrinsic value ($20.02) significantly above current price ($5.22)
- Low P/E of 1.83 (though misleading due to non-recurring gains)
- Price/Sales of 0.25 is well below sector average
Watchpoints
- P/E likely distorted by one-time accounting events, not sustainable earnings
- Price/Book is negative (-1.03), indicating more liabilities than equity
- No Graham Number available due to unprofitability or negative book value
Future
20/100
Ref Growth rates
Positives
- Recent earnings surprises suggest possible turnaround catalysts
- Analyst target price of $8.67 implies 66% upside
Watchpoints
- Revenue growth YoY is -91.40%, worst-in-class
- No PEG ratio due to unreliable growth projections
- No forward earnings growth data available
Past
30/100
Ref Historical trends
Positives
- 3 out of last 4 quarters beat EPS estimates
- Some quarters show dramatic positive surprises (e.g., +281.8%, +392.3%)
Watchpoints
- Long-term price performance is catastrophic: -98.9% over 5 years
- History of large negative surprises (e.g., -89.3% in Q1 2023)
- EPS volatility is extreme, with swings from -$34 to +$3.50
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.02 indicates minimal short-term liquidity
- ROA of 30.86% is positive (though likely an anomaly)
Watchpoints
- Piotroski F-Score of 2/9 is critically low
- Operating margin of -102.72% is unsustainable
- No Altman Z-Score reported, increasing bankruptcy risk uncertainty
- Quick ratio of 0.86 indicates potential liquidity stress
- Debt/Equity and cash/debt figures unavailable, suggesting financial opacity
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
- Not applicable for biotech growth firms, but reflects no income cushion
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$5.22
Analyst Target
$8.67
Upside/Downside
+66.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ATRA and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ATRA
Atara Biotherapeutics, Inc.
Primary
|
-98.9% | -95.6% | -24.7% | -54.9% | -70.3% | +15.0% |
|
BDMD
Baird Medical Investment Holdings Limited
Peer
|
-89.3% | -90.0% | -87.4% | -49.5% | -26.9% | -10.4% |
|
NMTC
NeuroOne Medical Technologies Corporation
Peer
|
-88.5% | -57.8% | +32.2% | -19.5% | +1.4% | -12.1% |
|
RADX
Radiopharm Theranostics Limited
Peer
|
-74.1% | -74.1% | +6.5% | -35.6% | -2.5% | -1.7% |
|
RMTI
Rockwell Medical, Inc.
Peer
|
-90.9% | -57.7% | -11.7% | -22.2% | -11.7% | 0.0% |
ATR
Atara Biotherapeutics, Inc.
Primary
5Y
-98.9%
3Y
-95.6%
1Y
-24.7%
6M
-54.9%
1M
-70.3%
1W
+15.0%
BDM
Baird Medical Investment Holdings Limited
Peer
5Y
-89.3%
3Y
-90.0%
1Y
-87.4%
6M
-49.5%
1M
-26.9%
1W
-10.4%
NMT
NeuroOne Medical Technologies Corporation
Peer
5Y
-88.5%
3Y
-57.8%
1Y
+32.2%
6M
-19.5%
1M
+1.4%
1W
-12.1%
RAD
Radiopharm Theranostics Limited
Peer
5Y
-74.1%
3Y
-74.1%
1Y
+6.5%
6M
-35.6%
1M
-2.5%
1W
-1.7%
RMT
Rockwell Medical, Inc.
Peer
5Y
-90.9%
3Y
-57.7%
1Y
-11.7%
6M
-22.2%
1M
-11.7%
1W
0.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
1.83
Forward P/E
11.66
PEG Ratio
N/A
P/B Ratio
-1.03
P/S Ratio
0.25
EV/Revenue
0.27
EV/EBITDA
0.91
Market Cap
$37.64M
Profitability
Profit margins and return metrics
Profit Margin
15.4%
Operating Margin
-102.72%
Gross Margin
46.76%
ROE
N/A
ROA
30.86%
Growth
Revenue and earnings growth rates
Revenue Growth
-91.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.02
Good
Quick Ratio
0.86
Poor
Cash/Share
$1.9
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-05
$N/A
2025-11-12
$-0.32
+51.9% surprise
2025-08-11
$0.19
+392.3% surprise
2025-05-15
$3.5
+281.8% surprise
Healthcare Sector Comparison
Comparing ATRA against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
1.83
This Stock
vs
75.44
Sector Avg
-97.6%
(Discount)
Profit Margin
15.4%
This Stock
vs
-16.28%
Sector Avg
-194.6%
(Weaker)
Revenue Growth
-91.4%
This Stock
vs
124.04%
Sector Avg
-173.7%
(Slower)
Current Ratio
1.02
This Stock
vs
4.47
Sector Avg
-77.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ATRA
Atara Biotherapeutics, Inc.
|
BEARISH | $37.64M | 1.83 | -% | 15.4% | $5.22 | |
|
BDMD
Baird Medical Investment...
|
BEARISH | $37.83M | - | -8.0% | -10.0% | $1.03 | Compare |
|
NMTC
NeuroOne Medical...
|
BEARISH | $37.01M | - | -146.3% | -58.3% | $0.73 | Compare |
|
RADX
Radiopharm Theranostics Limited
|
BEARISH | $36.1M | - | -92.1% | -286.2% | $4.58 | Compare |
|
RMTI
Rockwell Medical, Inc.
|
BEARISH | $36.0M | - | -15.3% | -7.7% | $0.91 | Compare |
ATRA
Atara...
BEARISH
Mkt Cap
$38M
P/E
1.8
ROE
-%
Price
$5.22
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-12 | PANACEA INNOVATION LTD | Beneficial Owner of more than 10% of a Class of Security | Sale | 80,554 | $489,019 |
| 2025-11-28 | PANACEA VENTURE | Beneficial Owner of more than 10% of a Class of Security | Option Exercise | 48,737 | $5 |
| 2025-11-17 | NGUYEN ANHCO T | Chief Executive Officer | Sale | 2,915 | $38,437 |
| 2025-11-17 | GRANT-HUERTA YANINA | Officer | Sale | 1,804 | $23,788 |
| 2025-08-18 | NGUYEN ANHCO T | Chief Executive Officer | Sale | 2,958 | $34,360 |
| 2025-08-18 | GRANT-HUERTA YANINA | Officer | Sale | 1,809 | $21,009 |
PANACEA INNOVATION LTD
Beneficial Owner of more than 10% of a Class of Security
2026-01-12
80,554 shares
·
$489,019
PANACEA VENTURE
Beneficial Owner of more than 10% of a Class of Security
2025-11-28
48,737 shares
·
$5
NGUYEN ANHCO T
Chief Executive Officer
2025-11-17
2,915 shares
·
$38,437
GRANT-HUERTA YANINA
Officer
2025-11-17
1,804 shares
·
$23,788
NGUYEN ANHCO T
Chief Executive Officer
2025-08-18
2,958 shares
·
$34,360
GRANT-HUERTA YANINA
Officer
2025-08-18
1,809 shares
·
$21,009
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
3 analysts
Canaccord Genuity
2026-01-13
Buy
Hold
Canaccord Genuity
2025-12-19
Buy
Buy
Past News Coverage
Recent headlines mentioning ATRA from our newsroom.
Newest → oldest
No matching news yet.